Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth.

Jan Strnadel1,2, Sunkyu Choi1,2, Ken Fujimura1,2

  • 1Department of Pathology, University of California, San Diego, La Jolla, California.

Cancer Research
|April 7, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical characteristics and associated factors of cholestasis in infant's ≤3 months with cytomegalovirus infection.

Frontiers in microbiology·2026
Same author

Degree of hypertension and subclinical coronary atherosclerosis in asymptomatic individuals without cardiovascular disease.

PloS one·2026
Same author

Atomic-scale insights into the interaction mechanism of carmustine on chitosan nanocarriers: A combined DFT and molecular dynamics study.

International journal of biological macromolecules·2026
Same author

Sex differences in the association of lipoprotein(a) with subclinical coronary atherosclerosis in asymptomatic individuals.

Journal of cardiology·2026
Same author

Reduced activity of two LPL C-terminal variants, p.Glu396Val and novel p.Trp417Cys: a clinical, biochemical and structural study.

Frontiers in physiology·2026
Same author

Comment on a submandibular gland-sparing radiotherapy study: A methodological and statistical perspective.

Clinical and translational radiation oncology·2026

Mutant KRAS in pancreatic cancer activates eIF5A and PEAK1, which promotes tumor growth by regulating YAP/TAZ transcription factors and stem cell programs. This signaling pathway is upregulated in PDAC patients, driving tumorigenicity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) is driven by mutant KRAS.
  • The eIF5A-PEAK1 signaling axis is implicated in aggressive cancer phenotypes but its downstream effectors are unknown.

Purpose of the Study:

  • To elucidate the downstream signaling pathways regulated by eIF5A-PEAK1 in PDAC.
  • To identify key mediators of eIF5A-PEAK1-driven tumorigenicity.

Main Methods:

  • Proteomics and informatic analyses of PEAK1-depleted PDAC cells.
  • Biochemical assays including co-immunoprecipitation.
  • Functional studies assessing 3D tumor sphere growth and gene expression.

Main Results:

Related Experiment Videos

  • PEAK1 regulates protein translation, cytoskeleton organization, and cell-cycle pathways.
  • YAP1 and TAZ transcription factors are key targets of eIF5A-PEAK1 signaling.
  • Inhibition of eIF5A-PEAK1 signaling reduces YAP/TAZ and stem cell factor expression, decreasing tumor growth; conversely, amplification enhances these processes.

    • Conclusions:

    • The eIF5A-PEAK1-YAP1-TEAD signaling module is upregulated in PDAC patients.
    • This pathway contributes to PDAC development by regulating stem cell programs and promoting tumorigenicity.